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VCPDominant mutations in the visual pigment Rhodopsin (Rh) cause retinitis pigmentosa (RP) characterized by
progressive blindness and retinal degeneration. The most common Rh mutation, RhP23H forms aggregates in
the endoplasmic reticulum (ER) and impairs the proteasome; however, the mechanisms linking Rh aggregate
formation to proteasome dysfunction and photoreceptor cell loss remain unclear. Using mammalian cell
cultures, we provide the ﬁrst evidence that misfolded RhP23H is a substrate of the ERAD effector VCP, an
ATP-dependent chaperone that extracts misfolded proteins from the ER and escorts them for proteasomal
degradation. VCP co-localizes withmisfolded RhP23H in retinal cells and requires functional N-terminal and D1
ATPase domains to form a complex with RhP23H aggregates. Furthermore, VCP uses its D2 ATPase activity to
promote RhP23H aggregate retrotranslocation and proteasomal delivery. Our results raise the possibility that
modulation of VCP and ERAD activity might have potential therapeutic signiﬁcance for RP.Science, Helmholtz Zentrum
uherberg, Germany. Tel.: +49
n.de (M. Uefﬁng).
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Protein misfolding and aggregation have devastating pathological
consequences but the cellular mechanisms responsible for protein
quality control and response to aggregate-induced stress are poorly
understood. Progressive degeneration of photoreceptor neurons and
blindness are the major pathological events in autosomal dominant
retinitis pigmentosa (RP), a disease often associated with mutations
in the visual pigment Rhodopsin (Rh) [1–3]. Rh is a G protein-coupled
receptor that initiates the phototransduction cascade and pathological
Rh mutations have been grouped into several classes, based on their
biochemical and cellular properties [4]. The most common rhodopsin
mutation, belonging to class II mutations, is the substitution of proline
23 to histidine (RhP23H) [5]. Mutant RhP23H, in contrast to wild-type
(WT) Rh forms aggregateswithin the endoplasmic reticulum (ER) and
impairs the proteasome [6–8], however, the molecular mechanisms
linkingRhP23H aggregates to photoreceptor cell death are incompletely
understood. In COS-7 cells, transfection of RhP23H led to formation of
cytoplasmic aggregates (aggresomes) that were ubiquitinated, co-
localized with the cytoplasmic chaperone Hsc70 and disrupted the
Golgi and the intermediate ﬁlament network [9]. Indeed, the
formation of Rh aggregates could have deleterious consequences for
the cell. Rh aggregates can exert direct toxic effects or may alter
cellular trafﬁcking, signaling, ER and proteasome function [7,9–12]. Incontrast to these gain-of-function effects (GOF), misfolded RhP23H can
recruit RhWT into aggregates and thus affect thematuration, trafﬁcking
and activity of RhWT, leading to loss of Rh function (loss-of-function
[LOF] mechanism; [9,13–16]). Whether retinal degeneration is caused
mainly by a GOF or a LOF mechanism, or both, is currently unclear.
The mechanisms that promote RhP23H aggregate clearance are
poorly understood. Degradation of mutant RhP23H in vitro requires
that the misfolded protein is N-glycosylated and depends on a
functional proteasome [9]; interestingly, proteasome inhibition
increased the level of misfolded RhP23H in the ER suggesting that the
proteasome is involved in the retrotranslocation of misfolded RhP23H
from the ER into the cytosol [9]. The identiﬁcation of factors
speciﬁcally involved in the extraction of misfolded Rh from the ER
would provide a means to test the contribution of Rh aggregates to
retinal degeneration.
The conformation of membrane and secreted proteins is evaluated
by a highly specialized quality control systemwithin the ER.Misfolded
proteins that do not pass ER quality control (ERQC) are selectively
recognized and cleared during a process called ER-associated
degradation (ERAD) that involves their export from the ER followed
by proteasomal degradation [17,18]. The homohexameric AAA
(ATPase associated with various cellular activities) ATPase valosin-
containing protein VCP/p97/cdc48/ter94 is the driving force for the
extraction of misfolded proteins from the ER and delivery to the
proteasome [19]. The protein consists of an N-terminal domain that
binds to diverse adaptors followed by two highly conserved AAA
domains (D1 and D2) involved in ATP binding and hydrolysis and a
C-terminal domain [20]. While the D1 domain is responsible for VCP
oligomerization [21], the D2 domain accounts for the major ATPase
425A. Griciuc et al. / Biochimica et Biophysica Acta 1803 (2010) 424–434activity of VCP [22]. During ERAD, binding of VCP to its substrates is
realized by co-factors containingUbiquitin regulatoryX (UBX) domain
[23];misfolded proteins are ﬁrst recognized by the Ufd1–Npl4 adaptor
complex which subsequently binds the N-terminal domain of VCP
[24,25].
Improper ERAD functioning is associated with several pathologies;
thus, excessive degradation of misfolded ΔF508-cystic ﬁbrosis
transmembrane regulator (CFTR), which is less prone to aggregation,
is deleterious for airway epithelial cell function [26]. In vitro,
decreasing VCP activity allows some of the mutant CFTR to escape
ERQC and reach the plasma membrane, leading to a partial rescue
of chloride ion efﬂux mediated by CFTR [27]. Retention of V2
vasopressin receptor (V2R) in the early secretory pathway causes
X-linked nephrogenic diabetes insipidus and core-glycosylated
disease-causing V2R mutants are degraded via VCP- and Derlin-1-
mediated ERAD [28]. On the other hand, mutant proteins like Ataxin-3
or TDP-43 are extremely prone to aggregation [29,30] and remark-
ably, VCP was found to co-localize and interact with these aggregates
in patients with neurodegenerative disease [31,32]. Moreover, VCP
also co-localized with Ubiquitin-positive inclusions in patients with
Alzheimer's and Parkinson's disease [33], raising the possibility
that VCP and ERAD impairment might have broad pathological
consequences.
Misfolded membrane proteins can be degraded by lysosomes and/
or by the ubiquitin/proteasome system. Moreover, despite the
prominent function of VCP as ERAD effector, the ATPases of the 19S
proteasome also function as retrotranslocators during ERAD [34,35]. It
thus remained unclear how misfolded RhP23H is cleared by the cell.
Here, we provide the ﬁrst evidence that misfolded RhP23H is a
substrate of the ERAD effector VCP. Using in vitro cell culture systems
we show that misfolded RhP23H co-localizes and forms a complex with
VCP. This interaction requires functional N-terminal and D1 ATPase
VCP domains. Furthermore, VCP uses its D2 ATPase activity to
promote RhP23H aggregate retrotranslocation and proteasomal deliv-
ery. Our results suggest thatmodulation of the ERADmachinerymight
have therapeutic signiﬁcance for RP.
2. Material and methods
2.1. Cloning
Plasmids encoding human Rh (WT and P23H) were provided by V.
Marigo. pEGFP-N1 vectors expressing RhWT and RhP23Hwere a gift from
M. Cheetham. To clone human VCP into the pcDNA3 vector, the full-
length VCP cDNA from the pOTB7 library vectorwas used. VCPK524A and
VCPR155H mutants were generated from the VCPWT construct using
QuickChangeII Site-Directed Mutagenesis Kit (Stratagene). To obtain
C-terminal GFP or Strep-Flag (SF)-tagged VCP, VCPWT and its variants
were subcloned into the pcDNA3-Strep-GFP or pcDNA3-SF-TAP vectors
respectively. SF-tagged human VCP domains were obtained by
PCR ampliﬁcation using pcDNA3-VCPWT as template and further
cloning into the pcDNA3-SF-TAP vector. The VCP domains generated
are: N (1–199 aa), D1 (200–470), D2 (471–806), ND1 (1–470) and
D1D2 (200–806). For the ND2 chimeric domain (1–199, 471–806),
individual N and D2 domains were ampliﬁed by PCR using VCPWT as
template and then cloned into the pcDNA3 vector using BamHI, EcoRI
and HindIII restriction sites.
2.2. Cell culture, DNA and siRNA transfection
SK-N-SH human neuroblastoma cells (from European Collection of
Cell Cultures) were grown and transiently transfected as described
[36]. HEK293 and mouse cone photoreceptor 661W (gift from M.R.
Al-Ubaidi) cell lines were cultured in DMEM supplemented with 10%
heat-inactivated fetal bovine serum and 1% penicillin/streptomycin
(Gibco). Cells were transiently transfected with 1 µg of Rh and VCPexpression plasmids using Effectene (Qiagen). The transfection
efﬁciency for different cell lines was: 80% for HEK293, 15% for SK-N-
SH and 10% for retinal 661W. All the constructs had similar expression
levels. The transfection efﬁciency was assessed in the following way:
cells were cultured on glass coverslips coated with poly-D-lysine
(Sigma); they were transfected with GFP construct and 24 h after
transfection, cells were ﬁxed in PFA and stained with DAPI (Sigma) in
order to reveal the presence of all living cells. The ratio between GFP-
transfected cells and the total number of living cells (i.e. the
transfection efﬁciency) was calculated for each condition using at
least two ﬁelds of ∼50 cells. VCP siRNA (sense sequence, GGGCA-
CAUGUGAUUGUUAU) and negative control n1 (non sense sequence)
were purchased from Ambion. 50 nM siRNAs were transfected using
Lipofectamine 2000 (Invitrogen).
2.3. Western blotting
Western blotting was performed according to standard techniques
using the following primary antibodies: anti-VCP (mousemonoclonal,
1/5000, Progen Biotechnik), anti-Rh (mouse monoclonal, 1D4, 1/
5000, Sigma and rabbit polyclonal, 1/5000, Afﬁnity BioReagents), anti-
Ubiquitin (mouse monoclonal, 1/8000, BD Biosciences), anti-Flag
(mouse monoclonal, M2, 1/5000, Sigma) and anti-β-Tubulin (mouse
monoclonal, 1/2000, Sigma). Secondary antibodies were horseradish
peroxidase-coupled (1/8000, Jackson Immunoresearch). Quantiﬁca-
tion of band intensity after ECL detection was performed using Image
Quant TL software (GE Healthcare).
2.4. Immunoprecipitation
For co-immunoprecipitation HEK293 cells were lysed 48 h after
transient transfection and IP was performed as described [7].
Detergent-soluble fractions were incubated with 2 µl of undiluted
anti-VCP (mouse monoclonal, Abcam) or anti-Rh (1D4) antibodies
coupled to protein G beads. Samples were eluted with 2× Laemmli
sample buffer.
For Flag precipitation assay, detergent-soluble fractions were
incubated with 10 µl of anti-Flag M2 agarose (Sigma) for 2 h at +4 °C.
The proteinswere elutedwith Flagpeptide (Sigma) in TBS at 200 µg/ml.
After methanol–chloroform precipitation, 2× Laemmli sample buffer
was added to samples.
2.5. Rh degradation assay
Cells were transfected with VCP siRNA or control, and after 20 h
were transfected with Rh. 20 h after Rh transfection, cell lysates were
collected at different time points within a 7.5 h period after inhibition
of protein synthesis by cycloheximide (100 µM, Sigma).
2.6. Proteasome inhibition assay
Proteasome inhibition was achieved by exposing HEK293 cells,
32 h after transfection, to 5 µMMG132 (Z-Leu-Leu-Leu-al, Sigma). For
the VCP-dependent degradation assay of Rh, cells were lysed after
16 h of incubation with MG132 and the lysates were analyzed by
Western blotting. For the co-IP experiment, cells were lysed after 8 h
of incubation with MG132 and the IP experiment was performed. For
immunoﬂuorescence, 661W retinal cells and SK-N-SH cells were ﬁxed
and labeled after 8 h of incubation with 5 µM of the MG132 inhibitor.
2.7. Immunoﬂuorescence
48 h post-transfection, cells were ﬁxed and labeled as described
[36]. For co-localization experiments, immunoﬂuorescent labeling
was performed using antibodies directed against VCP (mouse
monoclonal, 1/500, Abcam) and against Calnexin (rabbit polyclonal,
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channel. Secondary antibodies were Alexa 568-conjugated goat anti-
rabbit (1/1000, Invitrogen) and cy5-conjugated goat anti-mouse (1/
1000, Jackson Immunoresearch). For the Rh degradation assay, Rhwas
labeled with anti-Rh antibody (1D4, mouse monoclonal, 1/200,
Sigma) and Calnexin was labeled with anti-Calnexin antibody. VCP-
GFP was visualized through GFP signal in the FITC channel. Secondary
antibodies were Alexa 568-conjugated goat anti-mouse (1/1000,
Invitrogen) and cy5-conjugated goat anti-rabbit (1/1000, Jackson
Immunoresearch). For localization of Flag-tagged constructs, Flag was
labeled with an anti-Flag antibody (rabbit polyclonal, 1/200, Sigma)
and ER was revealed using the pDsRed2-ER tracker (Clontech).
Secondary antibody was Alexa 488-conjugated goat anti-rabbit
(1/1000, Invitrogen). The ER tracker was visualized through the
TRITC channel. Images were acquired using a Carl Zeiss LSM 510 laser-
scanning confocal microscope.
2.8. Quantiﬁcation of average levels of intracellular Rh aggregates
Pictures displaying the distribution of Rh in transfected cells were
used. The area corresponding to intracellular Rh aggregates was
carefully delineated and the average intensity of the signal was
determined within this area. To correct for differences in background
intensity, an area devoid of aggregates (generally the nucleus, inferred
from the Calnexin/ER labeling) was used and the average intensity in
this area was substracted from the average intensity of Rh aggregates.
The quantiﬁcations were performed using the ImageJ software and
the values are represented in arbitrary units. At least 15 cells were
analyzed per condition. Results were considered signiﬁcant for a
p-value inferior to 0.05, using the Student's t-test.
3. Results
3.1. VCP co-localizes with Rh aggregates in vitro
We used immunoﬂuorescence to determine the subcellular
localization of Rh-containing aggregates and VCP. We transfected
mouse retinal 661W or human neuroblastoma SK-N-SH cells with
plasmids encoding either RhWT or mutant RhP23H, tagged with GFP.
We used a VCP speciﬁc antibody [32] to label the endogenous VCP in
these cells and a Calnexin-speciﬁc antibody to highlight the ER.
Transfected cells were treated with the proteasome inhibitor MG132
dissolved in DMSO, or with DMSO only. In 661W and SK-N-SH cells
treated with DMSO, we found that RhWT is correctly targeted at the
plasma membrane (Fig. 1A,M), although some RhWT-containing
aggregates were detected, probably as a result of overexpression
[7,9]; in contrast, RhP23H formed many cytoplasmic aggregates
(Fig. 1G,S). Higher resolution images of selected portions from these
pictures can be found in Fig. S1. We quantiﬁed the average signal
intensity corresponding to these cytoplasmic Rh-containing aggre-
gates (values indicated in column 1) and found a signiﬁcant increase
in signal intensity in cells expressing RhP23H vs. RhWT (661W cells:
RhP23H vs. RhWT p<0.001; SK-N-SH cells RhP23H vs. RhWT p<0.01,
Student's t-test; at least 15 cells were quantiﬁed/condition). The
RhP23H-containing aggregates partially co-localized with the ERFig. 1. VCP co-localizes with aggregated Rh in mouse retinal 661W and SK-N-SH cells. Im
column), endogenous VCP (blue, second column) and the ER marker Calnexin (red, third col
V1′) treated with either DMSO (rows 1, 3, 5 and 7) or the proteasome inhibitor MG132 disso
column) while higher magniﬁcation of insets from merged pictures is shown in column
aggregates and is indicated in the ﬁrst column. RhWT is mainly localized at the plasma mem
aggregates within the cytoplasm (row 2); RhWT-containing ER aggregates co-localize with VC
the cytosol (white arrows in G1′) and partially co-localizes with VCP in the ER (G1, G1′). Prot
co-localization between RhP23H and VCP (J1′, black arrows). In SK-N-SH cells, RhWT localize
cytoplasmic RhWT aggregates (row 6). RhP23H localizes to the ER (S1′, black arrows) and ou
RhP23H aggregates within the ER (V1′, black arrows). Scale bar in A1–V1 is 20 µm and in A1marker Calnexin and with VCP (Fig. 1G1,S1 and black arrows in
Fig. 1G1′,S1′; see also Fig. 5). Some of these RhP23H-containing
cytoplasmic aggregates were not foundwithin the ER (Fig. 1G1,S1 and
white arrows in Fig. 1G1′,S1′), suggesting that they were extracted
from the ER and delivered to the cytosol, probably during their
processing for ERAD. While the localization of endogenous VCP is
mainly nuclear in both cell types transfected with RhWT (Fig. 1B,N),
VCP is localized to the ER in cells expressingmutant RhP23H. (Fig. 1H,T;
[37]). In control experiments, we determined that transfection with a
plasmid encoding only GFP does not lead to aggregate formation and
that under these conditions, VCP expression remains nuclear (data
not shown).
To determine whether Rh-containing aggregates are degraded
by the proteasome, we used the proteasomal inhibitor MG132 to
inhibit this degradation pathway in 661W or SK-N-SH cells. Inhibition
of the proteasome signiﬁcantly increased the load of cytoplasmic
Rh-containing aggregates (Fig. 1: D vs. A, J vs. G, P vs. M and V vs. S);
the quantiﬁcation of average signal intensity corresponding to these
cytoplasmic Rh-containing aggregates also conﬁrmed a signiﬁcant
increase in Rh aggregate load after proteasomal inhibition (661W
cells: RhWT vs. RhWT+MG132 p<0.001; RhP23H vs. RhP23H+MG132
p<0.05; SK-N-SH cells: RhWT vs. RhWT+MG132 p<0.05; RhP23H vs.
RhP23H+MG132 p<0.01; Student's t-test; at least 15 cells were
used/condition). The levels of both RhWT- and RhP23H-containing
aggregates increased, suggesting that both RhWT and RhP23H are
degraded by the proteasome. Proteasomal inhibition led to the
accumulation of RhP23H-containing aggregates within the ER
(Fig. 1J1′,V1′, black arrows) and interestingly, the co-localization
between these aggregates and the endogenous VCP increased
(Fig. 1J1,J1′,V1,V1′). Taken together, these results suggest that
expression of RhP23H leads to the formation of cytoplasmic aggregates
that are substrate of the proteasome and partially co-localize with the
ERAD effector VCP.3.2. VCP forms a complex with Rh aggregates
The observation that Rh-containing aggregates are degraded by
the proteasome raises the possibility that these aggregates are a
substrate of the ERAD machinery, the cellular system responsible for
the extraction of misfolded proteins from the ER and their delivery to
the proteasome. Given the co-localization between RhP23H aggregates
and the ERAD chaperone VCP, we asked whether aggregated RhP23H
and VCP are found in a complex. To this aim, we performed
immunoprecipitation (IP) experiments in HEK293 cells. We trans-
fected the cells with either RhWT or RhP23H, and found that RhP23H, in
contrast to RhWT led to the formation of high molecular weight
(HMW) aggregates, the major species migrating at >170 kDa.
(Fig. 2A). We then immunoprecipitated the endogenous VCP from
these cells and tested for the presence of Rh using an Rh-speciﬁc
antibody [9]. Our analysis revealed that RhP23H aggregates form a
complex with VCP; VCP also interacted with RhWT aggregates, which
displayed reduced levels compared to RhP23H. Although RhWT at
endogenous levels does not form aggregates in vivo, aggregates have
been reported as a result of overexpression [7]. We found VCP also
interacting with other non-Rh-containing aggregates (Fig. 2A),munoﬂuorescence pictures revealing localization of transfected Rh-GFP (green, ﬁrst
umn) in mouse retinal 661W (A–L, A1, A1′–J1, J1′) or SK-N-SH cells (M–X, M1, M1′–V1,
lved in DMSO (rows 2, 4, 6 and 8). Co-localization is revealed in merged pictures (fourth
5. The average intensity of the green signal within the cytoplasm is a measure of Rh
brane in 661W cells (row 1). Proteasome inhibition leads to an accumulation of RhWT
P (black arrows in D1′). Mutant RhP23H accumulates in the ER (black arrows in G1′) and
easome inhibition increases the pool of RhP23H aggregates within the ER (J–L, J1) and the
s to the plasma membrane (row 5), while proteasome inhibition increases the pool of
tside of the ER (S1′, white arrows), while proteasome inhibition increases the pool of
′–V1′ is 5 µm.
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Fig. 2. VCP forms a complex with Rh aggregates in vitro. HEK293 cells were transfected with RhWT or RhP23H and endogenous VCP (A) or total Rh (B) was immunoprecipitated with
anti-VCP (A) or anti-Rh (B) antibody, while Immunoglobulin G (IgG) was used as negative control (A, B). The immunoprecipitates were analyzed by WB for (A) Rh (output, upper
panel), Ubiquitin (output, middle panel) or VCP (output, lower panel) or for (B) VCP (output, upper panel), Ubiquitin (output, middle panel) and Rh (output, lower panel). The
presence of Rh (A) or VCP (B) was revealed in input lysates (input). RhP23H and RhWT aggregates form a complex with VCP, while no interaction between VCP and Rhmonomers was
observed (A).
428 A. Griciuc et al. / Biochimica et Biophysica Acta 1803 (2010) 424–434suggesting that VCP has a broader role in aggregate recognition that
extends beyond misfolded Rh [33] and/or that VCP itself might be
ubiquitinated. No signal could be detected when the anti-VCP
antibody was replaced with Immunoglobulin G (IgG) (Fig. 2A). We
then performed the reverse experiment and transfected HEK293 cells
with either RhWT or RhP23H, after whichwe precipitated Rh aggregates
with an Rh antibody and assessed for the presence of VCP (Fig. 2B).
Similarly, we found that both WT and mutant Rh aggregates formed a
complex with VCP, although more aggregates are formed when
RhP23H was transfected. We then used a Ubiquitin-speciﬁc antibody to
label polyubiquitinated proteins. We found that Rh aggregates are
polyubiquitinated, and as expected, we detected a stronger signal for
RhP23H than RhWT aggregates (Fig. 2B). This suggests that the interaction
betweenVCP and polyubiquitinated Rh aggregatesmight promote their
proteasomal delivery. In a parallel experiment, we transfected cells
with RhWT or RhP23H and pulled down polyubiquitinated proteins using
apolyubiquitin afﬁnity resin.We found similarly, that polyubiquitinated
Rh aggregates interacted with VCP (data not shown). We also
assessed the interaction between Rh aggregates and VCP after
inhibition of the proteasome with MG132; interestingly, proteasome
inhibition enhances the interaction between Rh aggregates and
VCP (in line with Fig. 1), further suggesting that ER-retained misfolded
Rh is a substrate of VCP (Fig. S2). Taken together, these experi-
ments indicate that VCP forms a complex with polyubiquitinated
RhP23H aggregates, probably during their processing by the ERAD
machinery.
3.3. VCP interaction with misfolded Rh requires its ND1 domains
We next analyzed the structural requirements of VCP for its
interaction with aggregated Rh. We created several Flag-tagged
constructs for full-length (FL) VCP and deletion constructs represent-
ing domains of VCP: N-terminal, D1, D2, ND1, ND2 and D1D2 (Fig. 3A).
To understand which domains of VCP mediate the interaction with Rh
aggregates, we performed IP experiments in HEK293 cells transfected
with these tagged constructs and with RhP23H. As expected, FL VCP
forms a complex with RhP23H aggregates. The individual N and D2
domains are dispensable for the interaction between VCP and RhP23H
aggregates, while D1 and D1D2 domains displayed weaker binding,
showing that the D1 domain of VCP is necessary for interaction with
aggregates (Fig. 3B). Furthermore, the presence of the ND1 domaindisplayed the same binding efﬁcacy as the FL VCP suggesting that the
presence of both D1 and N-terminal domains of VCP is sufﬁcient for
optimal binding of VCP to Rh aggregates. To rule out that the lack of
interaction between VCP deletion constructs and RhP23H is caused by
the absence of these truncated proteins from the ER, we determined
their subcellular localization in HEK293 cells. We found that all FL and
truncated VCP forms show extensive co-localization with the DsRed-
ER tracker, indicating that they localize to the ER (Fig. 3C). Because the
D1 domain regulates VCP hexamerization required for proper
functioning during ERAD [38] and the N-terminal domain binds the
aggregate-recruiting complex Ufd1–Npl4, it appears that both a
proper higher-order structure and proper interaction with adaptor
complexes are needed for VCP to recognize its substrates during
ERAD.
3.4. VCP is required for degradation of misfolded Rh
Considering that misfolded RhP23H co-localizes and interacts with
VCP, we hypothesized that RhP23H aggregates are a substrate of VCP
during ERAD. To test this hypothesis, we modiﬁed VCP levels in vitro
and evaluated the consequences of altered VCP levels on the clearance
of misfolded Rh. To determine whether VCP is required for
degradation of misfolded RhP23H, we knocked down VCP function in
HEK293 cells expressing mutant RhP23H (Fig. 4A). We used a
previously published VCP siRNA [39] and a nonsense sequence as
negative control and found that cells treated with VCP siRNA, but not
negative control, displayed a strong reduction of VCP protein levels
(Fig. 4A). 40 h after knock-down, we added cycloheximide (CHX) to
suppress de novo protein synthesis and analyzed the samples
collected at various time points. Knock-down of VCP leads to
accumulation of HMW Rh-containing oligomers and aggregates,
indicating that VCP activity is required for degradation of RhP23H
aggregates. Similar conclusions were reached when VCP function was
decreased in cells overexpressing RhWT (data not shown). We then
investigatedwhether VCP activity is sufﬁcient to promote degradation
of RhP23H aggregates (Fig. 4B). Cells transfected with RhP23H and with
increasing amounts of VCP plasmid displayed a dose-dependent
reduction of RhP23H aggregates, suggesting that VCP activity is
sufﬁcient to promote clearance of misfolded Rh. We then asked
whether Rh aggregates are degraded by the proteasome. We used the
proteasome speciﬁc inhibitor MG132 that we added to cells
Fig. 4. VCP is required for degradation of Rh aggregates in vitro. (A, B) HEK293 cells were transfected with RhP23H together with either VCP or control siRNA (A), or with increasing
amounts of VCPWT construct (B). (A) Cell lysates were collected after different durations of cycloheximide (CHX) treatment and probed for Rh. siRNA of VCP strongly decreases
degradation of RhP23H, and high molecular weight (HMW) Rh aggregates are formed. (B) Dose-dependent mediated degradation of RhP23H aggregates by VCP. Increasing VCP levels
(revealed by VCP antibody, middle panel) leads to a decrease in RhP23H aggregates (upper panel). (C) VCP-mediated degradation of RhP23H requires a functional proteasome. HEK293
cells were co-transfected with RhP23H and with increasing amounts of VCPWT followed by treatment with the proteasome inhibitor MG132 (or with DMSO as control). Proteasome
inhibition severely impairs degradation of Rh aggregates. Rh HMW aggregates (Agg, arrowhead) are indicated. β-Tubulin served as loading control.
Fig. 3. The D1 domain of VCP is required for interaction with RhP23H aggregates. (A) Schematic representation of Flag–VCP fusion proteins and summary of binding results. (B) Flag
pull-down experiments in HEK293 cells using an anti-Flag antibody. Bound RhP23H aggregates were detected using Rh (output, upper panel) or Ubiquitin (output, middle panel)
antibodies. Flag antibody was used to detect immobilized Flag bait proteins (output, lower panel). Full-length VCP (FL) was found in a complex with RhP23H aggregates. Weaker
binding was seen for the D1 and D1D2 domains, while the ND1 domain displayed the same binding efﬁcacy as the FL VCP. The N and D2 domains of VCP are dispensable for its
interaction with RhP23H aggregates. (C) HEK293 cells were transfected with the indicated Flag–VCP fusion constructs (green) and with ER tracker (red) and the localization of the
Flag signal and the ER tracker is shown in merged pictures. The different Flag–VCP fusion constructs localize mainly within the ER. Scale bar is 20 µm.
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VCP plasmid. Proteasomal inhibition severely impaired degradation of
RhP23H aggregates, and led to the massive accumulation of RhP23H
oligomers and HMW aggregates (Fig. 4C), indicating that the
degradation of RhP23H aggregates requires the proteasome. Taken
together, these results suggest that VCP is both required and sufﬁcient
to promote the degradation of Rh-containing aggregates, in a
proteasome-dependent manner.
3.5. D2 ATPase activity of VCP is required for degradation of misfolded Rh
Previous studies suggested that VCP uses ATP hydrolysis (via its D2
ATPase domain) to promote substrate retrotranslocation from the ER
to the cytosol and delivery to the proteasome [22,40]. The K524A
mutation in the D2 domain of VCP was shown to abolish the ATPase
activity associated with this domain and to induce accumulation
of misfolded ΔF508-CFTR [41], whereas the R155H mutation in the
N-terminal domain of VCP does not impair the ATPase activity [42]. To
test whether degradation of Rh aggregates requires the D2 ATPase
activity of VCP, we transfected mouse retinal 661W cells with either
RhWT or RhP23H plasmids andwith GFP-tagged plasmids encodingWT,
K524A or R155H mutant VCP. In cells transfected with RhWT and with
either GFP, VCPWT or VCPR155H, most of the overexpressed RhWT
properly localized at the plasma membrane and few intracellular
aggregates were detected (Fig. 5 rows 1, 2 and 4); the intracellular
RhWT aggregates showed a limited co-localization with VCPWT/R155H
(Fig. 5D1′,J1′, black arrows). Interestingly, cells co-transfected with
VCPK524A and RhWT displayed numerous intracellular aggregates that
showed an extensive co-localization with the ER and VCP (Fig. 5G1,
G1′, black arrows), suggesting that inhibition of VCP D2 ATPase
activity impairs clearance of the RhWT aggregates, which result from
Rh overexpression (Fig. 5 row 3). We quantiﬁed the average signal
intensity corresponding to intracellular Rh aggregates and found a
signiﬁcant increase in aggregate incidence in cells transfected with
VCPK524A (column 1, RhWT+VCPK524A vs. RhWT+VCPWT p<0.05,
Student's t-test). We then investigated the effect of WT and mutant
VCP overexpression on the clearance of misfolded RhP23H. Retinal cells
transfected with RhP23H and GFP displayed numerous intracellular
aggregates (Fig. 5M vs. A, RhWT+GFP vs. RhP23H+GFP p<0.001) that
showed extensive co-localization with the ER (Fig. 5 row 5). When
VCPWT was co-transfected with RhP23H, the load of RhP23H aggregates
decreased (RhP23H+GFP vs. RhP23H+VCPWT p<0.05) and some of the
remaining aggregates did not co-localize with the ER marker nor with
VCP (Fig. 5P1 and P1′, white arrows) suggesting that they were
extracted from the ER and accumulated in the cytosol. Co-transfection
with RhP23H and VCPR155H led to a similar situation: fewer aggregates
were detected (Fig. 5M,V) and some of these aggregates did not co-
localize with the ER marker nor with VCP (Fig. 5V1′, white arrows),
suggesting that they were extracted from the ER. When the ATPase
deﬁcient VCPK524A was co-transfected with RhP23H, the level of
intracellular aggregates was signiﬁcantly increased (Fig. 5M,P,S
RhP23H+GFP or RhP23H+VCPWT vs. RhP23H+VCPK524A p<0.0001)
and these aggregates showed extensive co-localization with the ER
marker and VCPK524A (Fig. 5S1,S1′, black arrows). Thus, inhibition of
D2 domain ATPase activity of VCP does not abolish co-localization
between VCPK524A and aggregated RhP23H, but strongly impairs
aggregate clearance.
To provide more quantitative evidence for a requirement of VCP
ATPase activity during ERAD of Rh aggregates and because of the lowFig. 5. ATPase activity of VCP is required for clearance of RhP23H aggregates. Immunoﬂuores
(rows 5–8) in 661W mouse retinal cells transfected with GFP (rows 1 and 5), or with WT (
mutant (rows 4 and 8) VCP-GFP constructs. Rh was detected with anti-Rh antibody (red, ﬁrs
was revealed using an anti-Calnexin antibody (blue, third column). The average intensity of
ﬁrst column. Expression of VCP ATPase deﬁcient construct leads to an increase in the amou
overexpression. All VCP forms co-localized with aggregated RhP23H (P1, S1, V1), either main
Thus, the D2 ATPase activity of VCP is not required for interaction with RhP23H but is requirtransfection efﬁcacy of mouse retinal 661W cells, we performed the
same experiments in HEK293 cells (Fig. 6). Similarly, we observed
that in the presence of VCPK524A, both RhWT and RhP23H-expressing
cells accumulate Rh aggregates (Fig. 6A). In agreement with the data
obtained from transfected 661W retinal cells, the presence of the
N-terminal mutant VCPR155H had no signiﬁcant effect on the turnover
of Rh aggregates (Fig. 6A). We then quantiﬁed the average intensity of
bands corresponding to Rh oligomers and aggregates (MW>60 kDa)
and found that while VCPWT or VCPR155H overexpression promoted
aggregate clearance, transfection with VCPK524A strongly impaired
aggregate clearance (Fig. 6B). We reached similar conclusions when
performing the experiments in the presence of the protein synthesis
inhibitor CHX at various time points (data not shown). In summary,
the D2 domain-associated ATPase activity of VCP is dispensable for its
interaction with Rh aggregates, yet appears to be speciﬁcally required
for their proper delivery to the proteasome for degradation.
The correlation between Rh aggregates and cell viability/death is
difﬁcult to establish in cell culture systems. Thus, we only observed a
minor decrease of cell viability in HEK293 cells (data not shown) and
SK-N-SH (Fig. S3C) cells expressing RhP23H vs. RhWT; these moderate
defects prevented us from analyzing the rescuing effects of VCP
manipulation in these systems. In addition, decreasing VCP function
by siRNA or by expression of VCPK524A leads to a signiﬁcant decrease
in cell viability (Fig. S3A,B) presumably via both ERAD-dependent
[41,43] and independent (e.g. effects on cell proliferation and strong
inhibition of NF-kB activation by FGF-2) mechanisms [44,45].
4. Discussion
Although mutations in the visual pigment Rh are the major cause
of photoreceptor loss and blindness in retinitis pigmentosa, the
pathological mechanisms linking misfolded Rh to cell death are
poorly understood. Class II mutant RhP23H forms insoluble aggregates
in the ER and impairs the proteasome, however, the mechanisms that
allow exit of misfolded Rh from the ER and proteasome targeting
remain unclear. Here, we show that misfolded RhP23H is a substrate of
the ATP-dependent chaperone VCP that promotes retrotranslocation
of misfolded proteins and delivers them to the proteasome. We found
that class II mutant RhP23H forms aggregates that co-localize and form
a complex with VCP. VCP requires functional N-terminal and D1
ATPase domains to interact with Rh aggregates and uses its D2 ATPase
activity to promote RhP23H aggregate retrotranslocation and protea-
somal delivery. Our results suggest that misfolded RhP23H is a new
ERAD substrate and raise the possibility that modulation of VCP and
ERAD activity might have potential therapeutic signiﬁcance for RP.
Using mammalian cell cultures, we found that VCP co-localizes
with intracellular Rh aggregates. In the presence of RhP23H, VCP
exhibited an extensive ER localization and was found to partially co-
localizewith these aggregates.We found thatmisfolded Rh aggregates
show a partial ER localization, raising the possibility that the other
non-ER pool of Rh aggregatesmight have been already translocated by
the ERAD machinery and accumulated in the cytosol. Our present
ﬁndings parallel previous studies in which misfolded RhP23H localized
to the ER and induced unfolded protein response together with
proteasomal inhibition [7,9,46]. To further investigate the role of the
proteasome in regulating Rh aggregate clearance and the interaction
between misfolded Rh and VCP, we used the speciﬁc proteasome
inhibitor MG132. Proteasome inhibition increased the levels of RhP23H
aggregates, further suggesting that these aggregates are degraded bycence pictures revealing the localization of overexpressed WT (rows 1–4) or P23H Rh
rows 2 and 6), D2 domain ATPase K524A mutant (rows 3 and 7) or N-terminal R155H
t column), VCP was visualized through GFP (green, second column) and the ER network
the red signal within the cytoplasm is a measure of Rh aggregates and is indicated in the
nt of cytoplasmic RhWT (row 3) and RhP23H (row 7), in contrast to WT and R155H VCP
ly outside the ER (P1′, V1′ white arrows) or inside the ER (P1′, S1′, V1′ black arrows).
ed for degradation of aggregated Rh. Scale bar is 20 µm (A1–V1) and 5 µm (A1′–V1′).
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Fig. 6. Clearance of RhP23H aggregates requires D2 ATPase activity of VCP. (A) Immunoblot revealing the levels of Rh in HEK293 cells transfected with WT or P23H Rh and with either
WT, K524A or R155H VCP. Transfection with VCPK524A strongly impairs Rh aggregate clearance. Rh aggregates (Agg, arrowhead) are indicated. β-Tubulin served as loading control.
(B) Quantiﬁcation of the level of Rh-containing oligomers and aggregates (MW>60 kDa); the intensity of high molecular weight bands was averaged from three different
experiments (* p<0.05 and **p<0.01 Student's t-test).
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also increased the levels of RhWT aggregates, suggesting that RhWT is
also a substrate of the proteasome. We found that cells transfected
with RhWT also displayed intracellular Rh aggregates (probably as a
result of overexpression) and RhWT-containing aggregates were also
found to co-IP with VCP. Wild-type Rh is known to undergo repeated
cycles of internalization–degradation during visual processing [47],
and proteasomal degradation is probably one/the pathway that
mediates RhWT degradation. The co-localization between RhP23H
aggregates and VCP was enhanced upon proteasome inhibition,
suggesting that increasing the level of ER Rh-containing aggregates
enhances the interaction between misfolded Rh and VCP. Indeed, our
co-IP experiment conﬁrmed that proteasome inhibition enhances the
interaction between misfolded Rh and VCP.
To speciﬁcally determine howmisfolded Rh interacts with VCP, we
performed co-IP experiments in cells transfected with WT or mutant
Rh. We found that endogenous VCP forms a complex with HMW
RhP23H aggregates. These RhP23H aggregates are polyubiquitinated,
suggesting that they are destined for proteasomal delivery. Interest-
ingly, we also found that VCP has a broader role in binding to HMW
aggregates, as polyubiquitinated aggregates devoid of Rh were also in
complex with VCP; these results do not rule out, however, that VCP
itself might be ubiquitinated, and additional studies could address this
possibility. VCP appears to interact with Ataxin-3 and TDP-43
neuronal inclusions [31,32], interacts with and promotes clearance
of folding-deﬁcient V2 vasopressin receptor mutants that cause X-
linked nephrogenic diabetes insipidus [28] and co-localizes with
Ubiquitin-positive intraneuronal aggregates in Alzheimer's and
Parkinson's diseases [33]. These observations raise the possibility
that VCP plays an important role in aggregate clearance in different
neuronal populations. To determine the structural requirements of
VCP for its interaction with misfolded Rh, we analyzed the binding
capacity of truncated VCP versions. We found that the presence of
both N-terminal and D1 domains is required for proper interaction
between VCP and RhP23H aggregates. Indeed, the N-terminal domain
recruits the Ufd1–Npl4 adaptors, which ﬁrst recognize and bind
misfolded proteins allowing their subsequent interaction and proces-
sing by VCP during ERAD [24,25]. The D1 ATPase domain of VCP was
previously shown to be required for VCP to form its hexameric and
catalytically active structure [38]; thus, a proper VCP oligomeric
structure is not only required for substrate processing but also for
substrate recognition. Taken together, these results suggest that both
a proper higher-order structure and access to aggregate-bound
adaptors are needed for VCP to exert its functions during ERAD.
Since misfolded RhP23H co-localized and interacted with VCP, we
hypothesized thatmisfolded RhP23H is a substrate of VCP during ERAD.We found that VCP is required for the degradation of RhP23H
aggregates since decreasing VCP activity using siRNA strongly
impaired the clearance of misfolded Rh. Conversely, when VCP is
overexpressed in cells expressing RhP23H, we observed a dose-
dependent reduction in Rh aggregates indicating that VCP is sufﬁcient
to promote degradation of Rh aggregates. We then determined that
RhP23H aggregates are cleared by the proteasome, similar to other
ERAD substrates. Interestingly, the proteasome has also been
suggested to participate in substrate retrotranslocation [9] and it
will be interesting to determine whether VCP cooperates with the
proteasome to promote retrotranslocation of misfolded proteins.
Taken together, these results suggest that VCP is both necessary and
sufﬁcient to deliver RhP23H aggregates to the proteasome for
clearance.
We ﬁnally investigated how VCP promotes clearance of Rh
aggregates. While overexpression of WT and N-terminal mutant
VCP effectively reduced aggregate load, overexpression of D2 ATPase
deﬁcient VCP failed to do so. A similar situation was observed
previously for the ERAD substrates ΔF508-CFTR [41] and TCRα [40].
Hence, we suggest that the D2 ATPase activity of VCP is the driving
force for retrotranslocation and proteasomal delivery of misfolded
RhP23H during ERAD.
Should VCP and ERAD activities be increased or decreased to
produce beneﬁcial functional effects on RhP23H-mediated pathology?
The manipulation of VCP activity in other situations involving protein
aggregates suggests that the effect of modulating VCP activity
depends on the nature of the mutant protein. Mutant ΔF508-CFTR,
similar to RhP23H is retained in the ER and is degraded by the ERAD
machinery [48]. Inhibition of VCP activity in cells expressing the
mutant ΔF508-CFTR allowed a fraction of the mutant protein to reach
the plasma membrane and partially rescued the phenotype induced
by excessive ERAD of mutant CFTR [27]. Since mutant RhP23H recruits
endogenous RhWT into aggregates [13–15], inhibition of VCP and
ERAD might allow the recovery of functional RhWT and maintenance
of photoreceptor integrity. ERAD inhibition might also promote
refolding and membrane delivery of mutant RhP23H, which could
mediate light transduction when at plasma membrane [8]. However,
misfolded RhP23H that accumulates in the ER interferes with
important functions mediated by the ER and induces ER stress
[8,46] together with proteasomal impairment [7], suggesting on the
contrary that aggregate clearance by increasing ERAD activity might
have beneﬁcial effects. In support of this hypothesis, an increase of
VCP activity was shown to mitigate neurodegeneration caused by
misfolded Ataxin-3 [31]. Thus, we suggest that the effect of
manipulating VCP and ERAD functions in RP depends on the relative
importance of LOF and GOF effects induced by misfolded Rh. Recent
433A. Griciuc et al. / Biochimica et Biophysica Acta 1803 (2010) 424–434works by Kang and Ryoo [49] and by Cheetham et al. [50] revealed
that the ERAD effectors EDEM1, EDEM2 and Hrd1 regulate Rh
aggregate dynamics. Overexpression of EDEM2 and Hrd1 was able
to partially suppress the neurodegeneration triggered by Rh1G69D
overexpression in Drosophila photoreceptor neurons, raising the
possibility that enhancement of ERAD is protective for photoreceptor
neurons, at least for the Rh1G69D-mediated retinal pathology and in
early stages, before onset of the dominant-negative effect exerted by
the mutant Rh on the maturation of WT Rh [49].
Because transfection with RhP23H vs. RhWT only led to a moderate
increase in cell dysfunction and VCPLOF severely impairs cell viability,
further improvements of the existent cell-based assays appear
necessary in order to address the connection between Rh aggregates,
VCP function and cell dysfunction in vitro. The use of postmitotic
neurons (e.g. derived from WT or transgenic mice) might overcome
the effects of VCP on cell proliferation and might maintain a high Rh
aggregate load in the postmitotic cell, similar to the situation in RP; in
addition, a recent study [51] suggests that postnatal neurons could be
maintained in culture, raising the possibility that manipulation of Rh
and VCP functions could be addressed in postmitotic and postnatal
neurons maintained in vitro.
Whether loss of mature Rh function (LOF effect) or aggregate
formation and associated toxic effects (GOF mechanism) cause RP is
currently unknown [4]. Alternatively, an interaction between both
GOF and LOF mechanisms might account for the wide range of
pathological changes that progressively impact on photoreceptor
neurons and ultimately cause disease [4]. Considering that misfolded
Rh could be at the origin of both GOF and LOF mechanisms, additional
studies in animal models for RP are required to clarify this issue. In
either case, a better understanding of the mechanisms responsible for
Rh quality control, protein refolding and aggregate clearance should
allow to effectively control the amount and composition of Rh
aggregates within the ER. The development of VCP and ERAD agonists
and antagonists might positively inﬂuence pre-clinical research
efforts in RP.
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